Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans

Core Insights - Geron Corporation is experiencing a bullish sentiment on Wall Street due to its plans to enhance the commercialization of Rytelo, a medication for anemia [2][3] - The company aims to reposition Rytelo for earlier treatment lines, particularly as a second-line therapy, and will implement strategies to increase physician awareness [2][3] - Despite stagnating sales of approximately $50 million in 2025, Geron is optimistic about significant growth in 2026 [2] Company Overview - Geron Corporation is a biopharmaceutical company focused on developing treatments for blood cancers, specifically myeloid hematologic malignancies [4] - Its primary product, Rytelo (imetelstat), is an approved telomerase inhibitor for certain patients with lower-risk myelodysplastic syndromes, with ongoing research for its application in other blood cancers [4] Analyst Ratings - Needham analyst Gil Blum has reiterated a Buy rating for Geron with a price target of $4 [3] - Leerink Partners has maintained an Outperform rating but reduced the price target from $3 to $2, while expecting the company to take necessary steps to improve Rytelo's performance [3]